Ipamorelin and CJC-1295 are frequently studied together because they work through complementary mechanisms — Ipamorelin acts as a GHRP (growth hormone releasing peptide) while CJC-1295 is a GHRH analogue. Together they produce a more robust and sustained GH pulse than either compound alone.
Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates pulsatile GH release with high selectivity — it does not significantly raise cortisol or prolactin. CJC-1295 (with DAC) binds to GHRH receptors on somatotrophs and extends the half-life of endogenous GHRH signaling. When combined, the two compounds act on different receptor populations, producing additive stimulation of GH secretion.
Preclinical studies in rodents show that combining a GHRP with a GHRH analogue produces 2–10x greater GH release than either peptide alone. A 2006 clinical trial of CJC-1295 demonstrated sustained GH and IGF-1 elevation over 6 days. No direct human RCTs exist for the combination, but the mechanistic rationale is well-established in the growth hormone literature.
Most research protocols administer both peptides simultaneously, typically 30–60 minutes before sleep to align with the natural nocturnal GH pulse. Some protocols split dosing to morning and evening. The combination is typically studied at Ipamorelin 200–300 mcg + CJC-1295 (no DAC) 100–200 mcg per injection.
The combination does not appear to produce additive side effects beyond those of each compound individually. The main considerations are water retention, mild fatigue, and potential desensitization with chronic high-frequency dosing. Cycling (e.g., 5 days on, 2 days off) is commonly used in research protocols to preserve receptor sensitivity.
Neither compound is required for the other to work, but the combination produces a synergistic GH pulse that neither achieves alone. Ipamorelin alone produces a clean, selective GH pulse; CJC-1295 alone produces a sustained but blunted pulse. Together they produce a larger, more sustained pulse.
Most research protocols use a 1:1 to 2:1 ratio of Ipamorelin to CJC-1295 (no DAC). A common combination is 200 mcg Ipamorelin + 100 mcg CJC-1295 per injection.
CJC-1295 with DAC has a much longer half-life (6–8 days) and is typically dosed once or twice weekly rather than daily. It can be combined with Ipamorelin but requires different timing — the Ipamorelin is still dosed daily while CJC-1295 DAC is dosed weekly.
IGF-1 levels typically begin rising within 2–4 weeks of consistent dosing. Body composition changes in research subjects are generally observed after 8–12 weeks of continuous use.
Purgo Labs provides research-grade peptides with independent third-party COAs and >99% purity verification.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.